Enteric Neurons In Parkinson'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Enteric neurons in the gastrointestinal tract are among the earliest affected in Parkinson's disease, with alpha-synuclein pathology detectable in the gut years before motor symptoms appear. This finding has led to the hypothesis that Parkinson's disease may originate in the gut and spread via the vagus nerve to the central nervous system.
- PGP9.5 (UCHL1) - pan-neuronal marker
- S100B - enteric glial marker
- TUBB3 (Beta-III Tubulin) - neuronal marker
- nNOS (NOS1) - nitrergic neurons
- ChAT - cholinergic neurons
- Calretinin - primary sensory neurons
- VIP - vasointestinal peptide neurons
- Alpha-synuclein (SNCA) - phosphorylated, aggregated
- pSer129 - phosphorylated serine 129
- Ubiquitin - inclusion marker
- LRRK2 - associated with enteric pathology
¶ Anatomy and Distribution
- Myenteric plexus (Auerbach): Between longitudinal and circular muscle
- Submucosal plexus (Meissner): Inner submucosa
- Mucosal innervation: Direct epithelial contact
- Sensory neurons: Detect stretch, chemical stimuli
- Motor neurons: Control smooth muscle, secretion
- Interneurons: Local processing
- Early appearance: Years before motor symptoms
- Phosphorylated at Ser129: Pathological form
- Enteric nervous system: All divisions affected
- Progression pattern: Rostral to caudal
- Esophagus: Early involvement
- Stomach: Moderate involvement
- Small intestine: Variable
- Colon: Common, especially in advanced disease
- Rectum: Late involvement
- Vagal pathway: Enteric → vagus nerve → dorsal motor nucleus
- Retrograde transport: From gut to brain
- Prion-like spread: Cell-to-cell transmission
- Timing: Prodromal phase
- Constipation: Most common GI symptom
- REM behavior disorder: Early marker
- Olfactory loss: Co-occurring gut dysfunction
- Enteric expression: Naturally present in ENS
- Aggregation triggers: Gut inflammation, oxidative stress
- Neuronal vulnerability: Specific subtypes
- Transspread: Via vagal nerve
- Elevated cytokines: TNF-α, IL-1β, IL-6
- Increased permeability: Leaky gut
- Dysbiosis: Altered microbiome
- Molecular mimicry: Cross-reactive immunity
- Complex I deficiency: As in brain
- Environmental toxins: From gut exposure
- Energy failure: Impaired neuronal function
- Early detection: Biopsy in prodromal PD
- Risk identification: Relatives of PD patients
- Biomarker potential: Stool, tissue
- Gut-targeted approaches: May slow progression
- Microbiome modulation: Probiotics, diet
- Anti-inflammatory: Reduce propagation
- Alpha-synuclein vaccines: May protect ENS
- Prokinetics: Improve motility
- Laxatives: Symptom management
- Dietary fiber: Constipation relief
- Gut-focused immunotherapy: Mucosal vaccination
- Microbiome transplantation: FMT
- Antioxidants: Reduce oxidative stress
The study of Enteric Neurons In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Braak H, et al. (2003). "Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease." Neurobiol Aging. 24(2):197-211.
- Wakabayashi K, et al. (1988). "Lewy bodies in the enteric nervous system." Acta Neuropathol. 76(3):217-221.
- Braak H, et al. (2006). "Gut enteric nervous system remains a major source of alpha-synuclein." Nat Rev Neurosci. 7(12):895-896.
- Sampson TR, et al. (2016). "Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease." Cell. 167(6):1469-1480.
- Clairembault T, et al. (2015). "Enteric alpha-synuclein: a key factor in Parkinson's disease?" J Neural Transm. 122(10):1407-1419.